Needham Maintains Buy on Surmodics, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a 'Buy' rating on Surmodics (NASDAQ:SRDX) but lowers the price target from $50 to $44.
November 08, 2023 | 10:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Surmodics' price target has been lowered from $50 to $44 by Needham, though the 'Buy' rating is maintained.
The lowering of the price target by Needham could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100